Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DDP-225
- Development stage
- Phase 2
- Lead developer
- Dynogen Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
DDP-225 is a small molecule thienopyrimidine analog that acts as both a selective noradrenaline reuptake inhibitor and a serotonin type 3 receptor (5-HT3) antagonist. This dual mechanism targets neurotransmitter systems involved in mood regulation and gastrointestinal function. The drug was developed for oral administration with the aim of treating irritable bowel syndrome (IBS), particularly diarrhea-predominant IBS (IBS-d), overactive bladder, major depressive disorder, and nausea/vomiting. It was originally developed by Mitsubishi Chemical and later licensed to Dynogen Pharmaceuticals[1][2][4][5][6].
- Other names
- DDP-225 hydrochloride hydrateDDP225 hydrochloride hydrateDDP 225 hydrochloride hydrateDDP-225 free base anhydrousDDP225 free base anhydrousDDP 225 free base anhydrous
02
Targets
NET (Norepinephrine Transporter)HTR3A (5-hydroxytryptamine receptor 3A)
Beyond the preview
Go deeper on DDP-225.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DDP-225.